Literature DB >> 16517979

Phosphorylated extracellular signal-regulated kinases are significantly increased in malignant mesothelioma.

Merivane de Melo1, Margaret W Gerbase, Joseph Curran, Jean-Claude Pache.   

Abstract

Tumorigenesis is associated with the activation of mitogenic signal transduction pathways. The expression of activated extracellular signal-regulated kinase (p-ERK) may play an important role in cell proliferation of malignant mesothelioma (MM). We compare the expression of p-ERK in 50 biopsy specimens of MM, non-small-cell lung cancer (NSCLC), and normal lung tissue. We hypothesized that phosphorylated extracellular signal-regulated kinase is increased in MM. We stained the sections by immunohistochemistry for activated ERK-1 and -2 and performed the quantification of the stained nuclei. Quantitative analysis of p-ERK showed a high percentage score in MM (30.3 +/- 4.6%) as compared with NSCLC (12.2 +/- 2.1%) (p<0.01) and control lung tissue (6.4 +/- 1.3%) (p=0.0002). Furthermore, p-ERK was found significantly higher in poorly differentiated NSCLC (17.7 +/- 3.1%) as compared with well-differentiated NSCLC (5.4 +/- 1.2%) (p<0.01). Our data show that the nuclear quantification of p-ERK is significantly increased in MM and poorly differentiated NSCLC in comparison to well-differentiated NSCLC and normal lung tissue. These results corroborate previous experimental studies that suggest a critical role of p-ERK in cell proliferation of malignant disease and may represent new targets for therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16517979     DOI: 10.1369/jhc.5A6807.2006

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  19 in total

1.  A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma.

Authors:  Craig W Menges; Yibai Chen; Brooke T Mossman; Jonathan Chernoff; Anthony T Yeung; Joseph R Testa
Journal:  Genes Cancer       Date:  2010-05-01

2.  Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.

Authors:  Stergios J Moschos; Ryan J Sullivan; Wen-Jen Hwu; Ramesh K Ramanathan; Alex A Adjei; Peter C Fong; Ronnie Shapira-Frommer; Hussein A Tawbi; Joseph Rubino; Thomas S Rush; Da Zhang; Nathan R Miselis; Ahmed A Samatar; Patrick Chun; Eric H Rubin; James Schiller; Brian J Long; Priya Dayananth; Donna Carr; Paul Kirschmeier; W Robert Bishop; Yongqi Deng; Alan Cooper; Gerald W Shipps; Blanca Homet Moreno; Lidia Robert; Antoni Ribas; Keith T Flaherty
Journal:  JCI Insight       Date:  2018-02-22

3.  ERK2 is essential for the growth of human epithelioid malignant mesotheliomas.

Authors:  Arti Shukla; Jedd M Hillegass; Maximilian B MacPherson; Stacie L Beuschel; Pamela M Vacek; Kelly J Butnor; Harvey I Pass; Michele Carbone; Joseph R Testa; Nicholas H Heintz; Brooke T Mossman
Journal:  Int J Cancer       Date:  2011-01-06       Impact factor: 7.396

4.  An extracellular signal-regulated kinase 2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury.

Authors:  Arti Shukla; Trisha F Barrett; Maximilian B MacPherson; Jedd M Hillegass; Naomi K Fukagawa; William A Swain; Kenneth J O'Byrne; Joseph R Testa; Harvey I Pass; Stephen P Faux; Brooke T Mossman
Journal:  Am J Respir Cell Mol Biol       Date:  2011-03-31       Impact factor: 6.914

5.  Extracellular signal-regulated kinase 5: a potential therapeutic target for malignant mesotheliomas.

Authors:  Arti Shukla; Jill M Miller; Christopher Cason; Mutlay Sayan; Maximilian B MacPherson; Stacie L Beuschel; Jedd Hillegass; Pamela M Vacek; Harvey I Pass; Brooke T Mossman
Journal:  Clin Cancer Res       Date:  2013-02-27       Impact factor: 12.531

Review 6.  Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.

Authors:  Angela Bononi; Andrea Napolitano; Harvey I Pass; Haining Yang; Michele Carbone
Journal:  Expert Rev Respir Med       Date:  2015-08-26       Impact factor: 3.772

7.  Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis.

Authors:  Arti Shukla; Marcus W Bosenberg; Maximilian B MacPherson; Kelly J Butnor; Nicholas H Heintz; Harvey I Pass; Michele Carbone; Joseph R Testa; Brooke T Mossman
Journal:  Am J Pathol       Date:  2009-10-08       Impact factor: 4.307

Review 8.  Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways.

Authors:  Nicholas H Heintz; Yvonne M W Janssen-Heininger; Brooke T Mossman
Journal:  Am J Respir Cell Mol Biol       Date:  2010-02       Impact factor: 6.914

9.  SV40-induced expression of calretinin protects mesothelial cells from asbestos cytotoxicity and may be a key factor contributing to mesothelioma pathogenesis.

Authors:  Thomas Henzi; Walter-Vincent Blum; Martine Pfefferli; Tadeusz J Kawecki; Valerie Salicio; Beat Schwaller
Journal:  Am J Pathol       Date:  2009-05-12       Impact factor: 4.307

10.  Extracellular signal-regulated kinase 5 and cyclic AMP response element binding protein are novel pathways inhibited by vandetanib (ZD6474) and doxorubicin in mesotheliomas.

Authors:  Mutlay Sayan; Arti Shukla; Maximilian B MacPherson; Sherrill L Macura; Jedd M Hillegass; Timothy N Perkins; Joyce K Thompson; Stacie L Beuschel; Jill M Miller; Brooke T Mossman
Journal:  Am J Respir Cell Mol Biol       Date:  2014-11       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.